c-erbB-2 and the “triple-state” in early breast carcinomas

Sivridis, Efthimios; Stamos, Charilaos; Fiska, Aliki; Nikolettos, Nikolaos; Koukourakis, Michael I.; Giatromanolaki, Alexandra

doi:10.1007/s12032-009-9252-6

Cited by 5 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Survival was directly connected to ER status and tumour size. The probability table (supplement 2) shows that low survival is particularly important when the patient have tumour of large size ([2 cm) and with low-ER expression (ER-), which is in agreement with previous clinical knowledge [26]. The computation of the joint probability of the network for the different patients (results not shown) shows that those with overexpression of BCL2, PR, ER and HER2 have the highest probability for high survival and vice versa; patients having a quadruple negative expression profile tumours have a high probability to survive less than 5 years.…”

Section: A Network Model To Study Association Between Bcl2 and Survivalsupporting

confidence: 86%

Bcl-2 expression and triple negative profile in breast carcinoma

et al. 2010

View full text Add to dashboard Cite

Many biomarkers for breast cancer prognosis have been proposed during the last two decades, among which HER2 and oestrogen receptors are of common use in routine clinical practice. However, in recent years, BCL2 has been recognized as an important prognostic parameter in human breast cancer, although its clinical utility is well established. The aim of this study was to examine the protein expression patterns of BCL2, HER2, oestrogen (ER) and progesterone receptors (PR) and to evaluate their correlation with survival and other prognostic parameters such as tumour size, histological grade and metastasis. We used a retrospective study including 84 Tunisian women with breast cancer. Immunohistochemistry was used to measure protein expression levels of several biomarkers. Association with conventional biopathological factors was analysed by SPSS (version13). The expression rates of BCL2, HER2, ER and PR were, respectively, 69, 62, 58.3 and 51.2%. In univariate analyses, BCL2 was highly correlated with both PR (P < 0.001) and ER (P = 0.006) and also with HER2 expression (P = 0.001). The triple negative profile showed a significant association with SBR (P = 0.016) and BCL2 expression (P = 0.02). In multivariate analyses, a significant association was maintained between BCL2 and both PR and ER (P = 0.02 and P = 0.004, respectively). Survival analysis showed that BCL2 expression was positively correlated with patients survival (P = 0.032). A Bayesian network analysis of all the variables confirmed the high value of BCL2 expression as a predictor of survival. As conclusion, BCL2 expression seems to be a very useful factor that should be in combination with HER2 and ER in breast cancer prognosis.

show abstract

Section: A Network Model To Study Association Between Bcl2 and Survivalsupporting

confidence: 86%

Bcl-2 expression and triple negative profile in breast carcinoma

et al. 2010

View full text Add to dashboard Cite

show abstract

“…The basal-like sub-cluster, characterized by the under-expression of these genes, is enriched for triple-negative (hormone receptor and HER2-negative) cancers and contains all cancer tissues of patients that are deceased (black dots) or have recurred (orange dots). Lobular breast carcinomas are known to be associated with better survival than ductal carcinomas [30] , [33] and triple-negative breast cancers have been associated with poor prognosis [34] . Also, in a meta-analysis of published breast cancer cDNA data, low GATA3 expression is linked with poor clinical outcome [35] .…”

Section: Resultsmentioning

confidence: 99%

Comparison of Breast Cancer to Healthy Control Tissue Discovers Novel Markers with Potential for Prognosis and Early Detection

et al. 2010

View full text Add to dashboard Cite

This study was initiated to identify biomarkers with potential value for the early detection of poor-outcome breast cancer. Two sets of well-characterized tissues were utilized: one from breast cancer patients with favorable vs. poor outcome and the other from healthy women undergoing reduction mammaplasty. Over 46 differentially expressed genes were identified from a large list of potential targets by a) mining publicly available expression data (identifying 134 genes for quantitative PCR) and b) utilizing a commercial PCR array. Three genes show elevated expression in cancers with poor outcome and low expression in all other tissues, warranting further investigation as potential blood markers for early detection of cancers with poor outcome. Twelve genes showed lower expression in cancers with poor outcome than in cancers with favorable outcome but no differential expression between aggressive cancers and most healthy controls. These genes are more likely to be useful as prognostic tissue markers than as serum markers for early detection of aggressive disease. As a secondary finding was that, when histologically normal breast tissue was removed from a distant site in a breast with cancer, 7 of 38 specimens displayed a cancer-like expression profile, while the remaining 31 were genetically similar to the reduction mammaplasty control group. This finding suggests that some regions of ipsilateral histologically ‘normal’ breast tissue are predisposed to becoming malignant and that normal-appearing tissue with malignant signature might warrant treatment to prevent new primary tumors.

show abstract

“…With the exception of CD31 molecule, all antigens under investigation were detected by a standard streptavidine technique [25]. In brief, sections were deparaffinized and peroxidase was quenched with methanol and H 2 O 2 3% for 15 min.…”

Section: Immunohistochemistrymentioning

confidence: 99%

The CD44+/CD24− phenotype relates to ‘triple-negative’ state and unfavorable prognosis in breast cancer patients

et al. 2010

Self Cite

View full text Add to dashboard Cite

Breast carcinomas have been reported to contain a subpopulation of CD44+/CD24- tumor cells with stem cell-like properties. This study investigates the significance of these two molecules in connection with tumor aggression and prognosis. The phenotypic profile of 139 breast carcinomas was investigated in paraffin sections using markers previously associated with stem cell-like properties (CD44, CD24), the "triple-state" (ER, PR, c-erb-B2), and angiogenesis (CD31). Tumors with >10% of CD44 and CD24 cancer cells were considered positive. The prevalence of CD44+ and CD24+ breast carcinomas in the series was 51.8% and 41.7%, respectively. Patients with the CD44(+)/CD24(-) phenotype had a 10-year lower median age at presentation and harbored tumors with a triple-negative state. They experienced an unfavorable prognosis. Lack of CD44 expression was associated with lymph node involvement, regardless of CD24 status, whereas the lack of both CD44 and CD24 was connected with high histologic grade and unfavorable prognosis which, notably, was the worse among all phenotypes. In multivariate analysis, the CD44(-)/CD24(-) phenotype, the nodal involvement, the vascular density and the ER-/PR-/c-erbB-2-profile were independent prognostic variables. It is concluded that assessment of the CD44/CD24 status may reveal distinct subgroups of breast cancer patients with different clinical behavior. The unsatisfactory response of the triple-negative tumors to current chemotherapy and their intimate link with the CD44(+)/CD24(-) phenotype, makes CD44 targeting an attractive therapeutic alternative for breast cancer patients. The strong association between the CD44(-)/CD24(-) phenotype and prognosis requires further investigation.

show abstract

c-erbB-2 and the “triple-state” in early breast carcinomas

Cited by 5 publications

References 31 publications

Bcl-2 expression and triple negative profile in breast carcinoma

Bcl-2 expression and triple negative profile in breast carcinoma

Comparison of Breast Cancer to Healthy Control Tissue Discovers Novel Markers with Potential for Prognosis and Early Detection

The CD44+/CD24− phenotype relates to ‘triple-negative’ state and unfavorable prognosis in breast cancer patients

Contact Info

Product

Resources

About